GoodRx Holdings (GDRX) Share-based Compensation (2019 - 2026)

GoodRx Holdings has reported Share-based Compensation for 8 years, with the latest figure at $16.5 million in Q1 2026.

• Quarterly Share-based Compensation fell 13.9% year-over-year to $16.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $74.0 million (down 20.56% YoY) and the FY2025 annual result came in at $76.6 million, down 22.62% from the prior year.
• Share-based Compensation retreated to $16.5 million in Q1 2026 per GDRX's latest filing, from $17.9 million in the prior quarter.
• Over five years, Share-based Compensation peaked at $194.5 million in Q2 2022 and troughed at -$23.2 million in Q2 2024.
• A 5-year average of $33.3 million and a median of $25.1 million in 2024 frame the typical range for Share-based Compensation.
• The sharpest annual moves came in 2022 and 2024: Share-based Compensation surged 2335.21% in 2022, then plunged 229.64% in 2024.
• Over 5 years, Share-based Compensation stood at $29.4 million in 2022, then dropped by 2.16% to $28.8 million in 2023, then fell by 27.17% to $21.0 million in 2024, then retreated by 14.5% to $17.9 million in 2025, then fell by 7.87% to $16.5 million in 2026.
• According to Business Quant data, Share-based Compensation over the past three periods registered $16.5 million, $17.9 million, and $49.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.